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Abstract: Vaccinia virus (VACV) has achieved unprecedented success as a live viral 
vaccine for smallpox which mitigated eradication of the disease. Vaccinia virus has  
a complex virion morphology and recent advances have been made to answer some of the 
key outstanding questions, in particular, the origin and biogenesis of the virion membrane, 
the transformation from immature virion (IV) to mature virus (MV), and the role of several 
novel genes, which were previously uncharacterized, but have now been shown to be 
essential for VACV virion formation. This new knowledge will undoubtedly contribute to 
the rational design of safe, immunogenic vaccine candidates, or effective antivirals in the 
future. This review endeavors to provide an update on our current knowledge of the VACV 
maturation processes with a specific focus on the initiation of VACV replication through to 
the formation of mature virions.  
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Vaccinia virus (VACV) is one of the most intensively studied members of the poxvirus family, 
primarily as a consequence of its unprecedented success as a live viral vaccine for smallpox, which 
mitigated eradication of the disease. Subsequent focus on VACV as a viral vaccine delivery platform 
has demonstrated great potential, and indeed, several experimental vaccines have been developed and 
tested in clinical trials including those for intractable infectious diseases, such as HIV and various 
therapeutic cancer vaccines [1,2]. Similar to other poxviruses, VACV is characterized by a large 
double-stranded DNA genome (192 kb), encoding for more than 200 proteins that function in virus 
entry, viral transcription, DNA and RNA synthesis, virion assembly and host immune suppression [3,4]. 
The large size of the VACV genome makes it highly amenable to transduction with multiple coding 
genetic inserts of almost limitless size and scope and because it resides in the cytoplasm there is little 
risk of inadvertent host genome integration events occurring. These fundamental and intrinsic 
characteristics of VACV, along with its proven capacity to generate lifelong and durable adaptive 
immune responses to encoded antigens, underpins its attractiveness as the basis of a robust vaccine 
vector platform technology. 
Vaccinia virus has complex virion morphology. The replication cycle of VACV commences with 
activation of the viral gene expression programme, core dissolution and DNA replication before 
crescent membrane formation. Crescent membranes assemble into immature virions which then 
undergo virion maturation. These mature virions (MV) can then be wrapped to form enveloped MV 
(EV) [5,6]. The exact mechanisms of these processes are still not fully understood despite decades of 
intensive study. However, following recent technological advances, genetic, proteomic, molecular 
biologic and microscopic studies have provided a more detailed picture of VACV assembly. These 
studies have contributed to our understanding of the VACV maturation process which will ultimately 
facilitate the rational creation of safer and more efficient vaccine vector platforms and will also 
potentiate the discovery of new classes of anti-viral drugs [7].  
In the last decade, two comprehensive reviews have detailed our current understanding of VACV 
structure and assembly [5,6], however, since then, advances have been made to answer some of the 
key outstanding questions, particularly the origin and biogenesis of the virion membrane, the 
transformation from immature virion (IV) to MV, and the role of several novel genes, which were 
previously uncharacterized, have now been shown to be essential for VACV virion formation. This 
review will endeavor to provide an update on our current knowledge of the VACV maturation 
processes with a specific focus on the initiation of VACV replication through to the formation of 
mature virions. 
2. Entry of Vaccinia into Host Cells 
Vaccinia virus has two main infectious forms, namely the MV and the extracellular EV. The virus 
can enter host cells by two routes, at a neutral pH viral membranes can directly fuse with cellular 
membranes while an acidic pH facilitates entry via the endosomal pathway [8,9]. Although largely 
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unknown, different mechanisms are believed to be employed by MV and EV to enter the cell [10]. 
Endocytosis is triggered by virus-receptor interactions, followed by intracellular transportation before 
membrane fusion. Four viral proteins involved in VACV attachment to host cells have been identified, 
including A26, A27, H3, and D8, which bind with glycosaminoglycan or laminin on the cell surface 
[11–15]. Membrane fusion is believed to be mediated or catalyzed by a large macromolecular 
assembly of viral proteins in the MV, which has been named the entry fusion complex (EFC). This 
complex consists of nine transmembrane proteins: A16, A21, A28, G3, G9, H2, J5, L5 and O3 and two 
additional viral membrane proteins, F9 and L1, have been designated as  
EFC-associated [16–29]. Two recent reviews papers have detailed recent advances in our understanding 
of the cell entry process and have described the function of each of these proteins and associated 
complexes in detail [10,30].  
3. Viral Factory Formation and Function 
Following uptake of virus and dissolution of the core particle, “viral factories” are formed. These 
factories are concentrated infection-specific cytoplasmic domains of uniform density [31] and are 
believed to be the sites for viral assembly and viral DNA replication. The origin of the viral factory is 
still unclear. Immediately following cellular infection and before the appearance of any specific viral 
structures, these factories are transiently surrounded by cellular ER-derived membrane cisternae [31,32],  
which suggests the factories are initially defined by cellular components.  
DNA replication and virion assembly occurs within viral factories [33,34] and co-located are the 
subsequently transcribed intermediate and late viral mRNAs. In addition, different lines of evidence, 
including the location of translation initiation factors and ribosomal proteins, and expression of 
different foreign proteins, support the notion that viral proteins are also translated within these 
factories [35]. Indeed, recent electron microscopy (EM) and tomography (ET) studies have definitively 
shown that the dense contents in these factories contain key proteins and membrane structures that are 
involved in membrane biogenesis, including pre-assembled D13 scaffolds, ruptured small ER 
membrane structures, and membrane assembly proteins [36,37].  
4. Crescent Formation  
The first distinguishable structures of virus morphogenesis are crescent membranes. In most 
electron micrographs, crescents are comprised of two distinct layers, an inner smooth layer that has the 
trilamellar appearance of a lipoprotein bilayer, and an external honeycomb lattice layer composed of 
trimers of the D13 protein [38–41]. Despite contradictory theories [38,40,42], most recent data from 
microscopic observations and biochemical, genetic, and topological studies, suggest the crescent 
membrane is clearly derived from the ER [36,43–46] rather than synthesized “de novo” [38]. The 
biogenesis process commences by rupture of the cellular membrane by VACV proteins functioning to 
generate an open membrane intermediate, which is stabilized by scaffold protein D13, and contributes 
to forming the crescent membrane [36,47]. At least nine genes have been shown to be essential for the 
formation of crescent membranes, including three structural components D13, A14, and A17, and  
six regulatory proteins, A6, A11, F10, H7, L2, and A30.5, which are all involved in membrane 
biogenesis and lately referred to as “viral-membrane assembly proteins”. The exact mechanism of how 
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the viral membrane forms has not yet been resolved; however recent efforts are revealing how these 
proteins cooperate to complete the first stage of VACV assembly.  
4.1. Essential Structural Proteins for Crescent Formation: D13, A14 and A17 
4.1.1. The Scaffold of Crescent Membranes—D13 
The scaffold protein D13 is expressed in the latter phase of infection. With a molecular weight  
of 62 kDa, it was the first gene identified as essential for membrane formation and it is now well 
characterized. In the 1960s, Dales and Mosbach described a “spicule” layer that comprised the convex 
surface of crescent and IV membranes [38]. Later on, three-dimensional deep-etch EM studies 
revealed the spicule layer as a continuous honeycomb lattice [48], consisting of D13 trimers [41] and 
arranged mostly in hexagons [49]. Several lines of evidence have demonstrated the essential role of 
D13 in VACV morphogenesis, including inhibition by the drug rifampin and inducible knockout 
mutant repression of D13 synthesis, both of which terminate virus replication [50–52]. In contrast,  
an amino acid change in D13 restores the functionality of D13 in the presence of the drug  
rifampin [53,54].  
The D13 lattice acts as a mechanical scaffold for the growing crescent membrane, and its membrane  
re-modelling capacity facilitates maintenance of the constant radius of curvature until the membrane 
closes to form complete spheres [36,48,55]. The D13 lattice preassembles to form rod-like structures, 
and binds with the ER to form a “crescent precursor” [36,47]. One question that has been raised is that 
since D13 has no transmembrane domain, how can it associate with crescent membranes to form  
the lattice structure? Recent evidence has indicated that this could occur through interactions between  
D13 and the membrane protein A17, as both immunoaffinity purification and Western blot analysis 
demonstrates D13 can associate with A17 and immunogold electron microscopy also shows a close 
association of A17 and D13 in crescent membranes. Furthermore binding of A17 to D13 was 
abrogated by truncation of the N-terminal segment of A17 [56]. The D13 lattice remains associated 
with the developing virions until the complete assemble of IV, when it is removed to form the MV 
(discussed in a later section).  
4.1.2. Key Proteins Anchored in the Virion Membrane—A14 and A17 
The structural transmembrane proteins A14, along with A17 are essential components of the virion 
membrane and are ~15 and 23 kDa respectively. They are both expressed late in infection and unlike 
D13 which is removed during the transformation of IV to MV, A14 and A17 are anchored and remain 
abundant in the MV membrane. Both in vitro and in vivo data has shown that A14 and A17 are 
synthesized in the membranes [43,57], and D13 interacts with A17 to form crescent precursors [58,59].  
The A14 protein spans the viral membrane twice, having a topology where both the N- and  
C- termini face internally into the core, and the central hydrophilic loop is exposed to the outer  
surface [5,60]. It forms disulphide-linked homodimers via Cys
71
, and this dimerization enhances virion 
integrity and stability [61]. Previously, two A14 sites were thought to be important for its function in 
membrane biogenesis, including an N
83
HS motif that can be glycosylated and a Ser
85
 site that can 
undergo phosphorylation by F10 protein kinase, however, neither of these modifications has 
Viruses 2014, 6 3791 
 
significant impact on A14’s biological competency [60]. Recently, two other crucial motifs have been 
identified that affect its biological function in vivo: N
9
YF which is located within the short hydrophilic 
region at the N terminus is important for maturation of IV to MV, whereas, P
39
TRTWK, within the 
hydrophilic loop that is exposed on the external surface of the virion membrane, is significant for both 
crescent enlargement and for MV production [59].  
Similar to A14, A17 also spans the viral membrane twice, but with opposite polarities, where  
an internal hydrophilic loop extends into the luminal space and the N- and C- termini are exposed to 
the outer face of the virion membrane [57,62]. Both N- and C- termini undergo cleavage at an AG↓X 
motif, but at different stages of morphogenesis. The N-terminus regulates the association and 
disassociation of D13 protein, which are essential for crescent formation and subsequently the 
transition from IV to MV [56,59]. The C-terminus plays important roles in the maturation of IV to MV 
and in MV infectivity [56,59]. The F10-mediated phosphorylation on Ser, Thr, and Tyr residues within 
the C-terminal tail is vital for these bio-functions [63,64].  
Repression of either A14 or A17 by inducible knockout leads to similar consequences, where 
crescent membrane formation is inhibited. Accumulations of large electron-dense virosomes, which 
contain viral membrane and core proteins, are observed in viral factories, and numerous clusters of  
25 nm diameter membrane vesicles are found in the cytoplasm [59,61,65–68]. The exact composition 
of the vesicles is unclear, but evidence indicates they could consist of open membrane sheets which are 
formed by rupture of ER membranes [69]. Noticeably, the A17-deficent vesicles appear less dense and 
larger in size than those seen in A14-deficent infections [59], and this may be caused by differences in 
their function and/or structural-contributions to the membrane biogenesis.  
4.2. Regulatory Proteins that are Essential for Viral Membrane Assembly  
4.2.1. Early Transcribed Membrane Regulatory Protein—L2  
The L2 protein is 10.2 kDa and highly conserved in all chordopox viruses, but only very  
recently has been revealed as essential for formation of crescent membranes. Distinct from all other 
membrane-associated proteins, it is expressed early in VACV infection and remains stably-associated 
with the developing virion during the replication cycle, ultimately becoming a membrane component 
of the MV [70]. Suppression of L2 by a conditional lethal mutant exhibited defects in crescent 
membrane formation [70]. Using a recombinant VACV containing a tagged L2 protein, L2 was 
detected co-localized with the ER throughout the cytoplasm including in the viral factories, and was 
present at the edges of the crescent membranes [44]. More recently, a VACV L2R deletion mutant has 
been constructed and revealed that without L2, replication was aborted prior to mature virion 
formation [45]. Two types of aberrant structures were seen by EM, including short crescents located  
at the surface of viroplasm, which still contained proteins destined to form the cores of mature virions, 
and “empty” IV-like membranes, which appeared to be derived from smooth ER membranes. 
Together, this evidence suggests that L2 has an important role in recruiting the ER and modulating its 
transformation into viral membranes [45]. 
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4.2.2. A Small, L2-Interacting Protein—A30.5 
The A30.5 protein was discovered only recently during purification of L2 proteins from VACV 
infected cells [46]. This ~5 kDa protein has a putative transmembrane domain, but no signal peptide or 
any conserved motif. Unlike L2, A30.5 is synthesized after DNA replication and co-localizes with the 
ER membrane and the L2 protein. An A30.5 deletion mutant has been constructed and in the absence 
of A30.5, VACV morphogenesis was interrupted. Large electron-dense cytoplasmic inclusions and 
clusters of D13-coated membranes that resembled crescents and immature virions devoid of viroplasm 
were observed. This study also provided further evidence supporting the ER origin of the VACV 
membrane, by showing that crescent-shaped membranes are contiguous with the ER membranes and 
oriented with the convex D13 lattice-coated side facing the lumen, while clusters of completed 
spherical IV-like structures are trapped within the expanded lumen. Therefore, the outer surface of  
the VACV virion is most likely derived from the luminal side of the ER membrane.  
4.2.3. A11, a Viral Factory-Located, and Membrane-Associated Protein  
The 40 kDa A11 protein is expressed late in VACV infection and is localized in the viral factories 
but is not a significant component of the MV. The protein self-associates to form homodimers or 
higher order structures and is phosphorylated independently of the viral F10 kinase [71]. Repression of 
A11 by inducible knockout blocks VACV morphogenesis, resulting in the accumulation of large, 
dense bodies and a similar phenotype is observed as to when the other essential genes to crescent 
formation are interrupted, such as H7, L2 and A6 [71,72]. Recent studies show that A11 is localized 
with the ER within viral factories and present at the edges of crescent membranes in close association 
with A6 [72,73]. Similarly to L2, A11 is also involved in recruiting ER for virus assembly, but 
differently, A11 is expressed at late infection, and can only be found in the viral factory [72]. We 
speculate that A11 could be involved in stabilizing the crescent membrane ends to prevent resealing 
(fusion) before DNA uptake. This could explain the observation that large, dense bodies were 
accumulated after knockout of A11, as crescent precursors may reseal and accumulate to form  
the dense areas.  
4.2.4. Trafficking Protein A6  
The 43 kDa A6 virion core protein plays an essential role in virion membrane biogenesis.  
It is expressed after viral DNA replication, and packaged in the core of the mature virion.  
Temperature–sensitive A6 mutants show that viral gene expression and viral factory formation is 
normal but virion morphogenesis is blocked [74]. A6 may also be involved in trafficking the 
membrane proteins to the virion assembly sites, as with repression of A6, some virion membrane 
proteins, such as A11, cannot localize in viral factories but are found scattered in the cytoplasm  
instead [73,75].  
4.2.5. H7, a Cytoplasmic Located Protein  
Synthesis of the 17 kDa H7 protein occurs late during VACV infection, however, unlike other late 
expression proteins, H7 is not incorporated into mature virion [76]. This protein is also conserved in all 
Viruses 2014, 6 3793 
 
vertebrate poxviruses, however it has no discernible functional motifs, nor non-poxvirus homologs.  
It localizes not only in viral factories but also throughout the cytoplasm, which suggests that H7 
function is not limited to viral factories. Deletion of the H7 gene results in defective localization of 
D13 and the other MV membrane proteins to viral factories, however, the specific role of H7 is still 
unclear [37]. Notably, phenotypic differences were observed between the H7-null mutant and  
H7-inducible mutants, whereby crescent membranes were formed in iH7 mutant without inducing 
agent, but not in the ΔH7 infected cells, suggesting that leaky expression occurred from the un-induced 
mutant. This apparently aberrant result clearly demonstrates the crucial role that H7 plays in the 
development of short crescent membranes, and that even a small or undetectable amount of H7 could 
facilitate this process.  
4.2.6. Major Protein Kinase in the Virion Core—F10  
The F10 protein is the major protein kinase found encapsulated in the virion core. It is a 50 kDa  
protein and expressed late during infection. Recombinant F10 protein has been shown to have kinase 
activity in vivo [77–79]. In addition, the F10 sequence has recognizable motifs associated with ATP 
binding and phosphotransfer, but other subdomains cannot be identified due to the high divergence 
from consensus motifs [80]. F10 is a dual-specificity protein kinase, which can directly phosphorylate 
serine, threonine, and tyrosine residues [64].  
Expression of F10 protein is essential for VACV morphogenesis. Different F10-knockout mutant 
viruses have been constructed to characterize its biological function, including temperature-sensitive 
mutants and inducible knockouts [77,78,80,81]. Under non-permissive conditions, the F10 mutants 
show a profound defect in virion morphogenesis prior to crescent formation, implying that protein 
kinase activity is required for processing the essential proteins for membrane biogenesis. Indeed, as 
discussed earlier, A14 and A17, along with other possible membrane associated proteins, are 
phosphorylated by F10. Furthermore, F10 is not only involved in the early stages of virion assembly, 
but also plays important role in the transition of IV to MV (discussed later).  
In summary, thus far, following viral fusion, the VACV genome is released and early transcription 
commences; L2 associates with the ER membrane and recruits it to viral factories, and possibly forms 
the boundary of the viral factory prior to producing crescent membrane; L2 interacts with A30.5  
(or other unidentified proteins) to rupture the ER membrane into small sections which then form  
the smooth closed membrane structure. Prior to, or during, this process, A14 and A17 are synthesized 
in the ER. The smooth membrane structures are then recruited, opened up, and presented to  
pre-assembled scaffolds of D13, where D13 interacts with A17 to form crescent precursors. During 
assembly of the crescent membrane, A11 stabilizes the end of the crescent to prevent it resealing, 
whereas A6 may play a role in transporting or controlling the transient association of A11 with the 
crescent end, during crescent assembly and before sealing, to complete the spherical immature virion 
(Figure 1). However, further studies are required to verify this assumption and to shed light on the 
identity of possibly unknown genes that are involved in this process.  
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Figure 1. Model of Vaccinia virus (VACV) crescent membrane formation. Early 
transcribed protein L2 associates with the ER membrane and recruits it to viral factories, 
then L2 interacts with A30.5 or other unidentified proteins to rupture the ER membrane 
into small sections, while A14 and A17 are synthesized in the membrane in a co-
translational fashion. Smooth membrane structures are recruited, opened up, and presented 
to pre-assembled scaffolds of D13, where D13 interacts with A17 to form crescent 
precursors. A11 stabilizes the end of the crescent to prevent it resealing, whereas A6 may 
play a role in transporting or controlling the transient association of A11 with the crescent 
end. 
5. Immature Virion Formation 
Crescents grow in length while maintaining the same curvature until they become closed circles or 
spheres in three dimensions, to form the immature virion (IV) [5,82]. Recent studies provide evidence 
that describes this process in further detail. Instead of growth in a continuous way, “independent 
crescents” or “crescent precursors” [36,47] assemble, possibly with the help of viral-membrane 
assembly proteins, into the spherical IV shape. As the crescent membranes develop, they are filled 
with viroplasm, which is known to contain viral core proteins and are uniform in density, but 
distinguishable from the surrounding factory [83]. Meanwhile, the viral genomic DNA is packed  
into the viroplasm before sealing of the IV membrane [36,82]. The detailed mechanisms of how  
the viroplasm associates with the growing crescent and how DNA is transported or incorporated into  
the virion remain unclear. However, a complex of seven VACV proteins has been identified that are 
required for this process to occur, along with regulatory protein E6 which is essential for core  
protein association.  
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5.1. Proteins Involved in Viroplasm-Membrane Association  
5.1.1. The Seven Protein Complex  
A group of seven core proteins has been identified that form a multimeric complex and are essential 
for the association of viroplasm and viral membrane, [84,85] including A15, A30, G7, D2, D3, J1, and 
F10 [81,84–87]. The members of the complex interact and stabilize each other, and repression of any 
one these proteins results in destabilization of the others [81]. The structure of the complex is 
unknown, however, the polypeptides comprising the complex appeared to be in equimolar ratios, 
except for J1, which may be present as a homodimer [85,88].  
The absence of any proteins in the complex exhibited similar phenotypes, in which apparently 
empty IVs with normal-looking viral membranes, accumulate and separate from the large masses of 
viroplasm [83–86,88,89]. These observations demonstrate their essential role in the process of 
viroplasm and membrane association; however, the detailed mechanism of how the complex  
functions is still unknown. Except for F10, the remaining six proteins do not have any recognizable 
structure/functional motifs which might imply that the complex plays a structural role. The obligatory 
role of F10 for A14 and A17 phosphorylation may indicate a potential interaction between the complex 
and the membrane protein. However, this requires further investigations 
5.1.2. E6 Is Also Involved in Membrane-Viroplasm Association 
The E6 virion core protein is ~60 kDa and highly conserved in all chordopox viruses, but with  
no distinguishing functional motif and no homolog in non-poxvirus organisms [90]. Although the 
detailed function of E6 is still unclear, the current evidence shows that E6 acts on the same pathway as 
the seven-protein-complex, promoting the association of viroplasm with viral membrane crescents.  
E6 inducible KO mutants yield a phenotype virtually identical to the “seven protein complex” mutants, 
in which accumulation of both membrane crescent and viroplasm sub-assemblies are observed [90,91]. 
5.2. How the Genome Becomes Incorporated into the Virion Remains Unclear  
Vaccinia genome DNA replicates in the cytoplasm and produces progeny genomes that will  
be incorporated into the virion [92]. The DNA is replicated as long concatemers that are resolved by  
the Holliday junction endonuclease A22 [93]. Genome replication is not coupled to VACV early 
morphogenesis, as genome maturation occurs normally even with interrupted crescent membrane 
formation [5]. The mechanism of how genome packaging into virions remains largely unknown.  
As discussed earlier, it is now clear that the genome DNA is trafficked into the IV before the sealing of 
the virion membrane [32,36,82]. However, several key questions are needed to be addressed in the 
future, what genes are involved in transporting the genome, what the mechanism for controlling 
genome copy number in the virion as the virus is large enough to accommodate multiple copies [94], 
and what is the signaling pathway for membrane sealing after genome encapsulation.  
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6. Transition of Immature Virus Particles to Mature Virions 
The next stage of morphogenesis transforms spherical IVs containing the nucleoid (IVNs) that are 
enclosed in a single membrane to form the first infectious particle, the intracellular MV. The MVs are 
characterized by a core that has biochemical and morphological features that are distinct from IVs. 
Two lateral bodies are observed either side of the core and these structures are enclosed by a lipid 
membrane to form the ‘brick-shaped’ MV. The proteome of MVs and IVNs are nearly identical with 
the exception of a few membrane proteins which are inserted during the transition of IVNs to MVs. 
This transition involves key proteolysis and redox reactions to remove the D13L scaffold and 
restructure the particle to a transcriptionally active and infectious virion (Figure 2).  
6.1. Removal of the D13 Scaffold is Necessary but Not Sufficient for the Transition of IVs to MVs 
The D13 scaffold that is characteristic of IVs no longer surrounds MVs. However, the signals for 
scaffold removal are not completely understood. Removal of the D13 scaffold correlates with 
proteolytic processing of A17 [56,59] and mutations that prevent cleavage of the N-terminus of A17 
produce aberrant MV; they contain a core and appear ostensibly normal within what is described as  
a balloon-like circular membrane surrounded by D13 [59]. The processing of A17 has been shown to 
be dependent on I7, using temperature sensitive or inducible mutants [95]. The I7 protein is a core 
component that appears eight hours post-infection and shares homology with cysteine proteinases [96].  
It is also responsible for processing the precursor forms of other core proteins (discussed later).  
In the absence of inducer, inducible I7 mutants fail to form MVs but result in the accumulation of IV, 
IVN and aberrant dense spherical particles that were identical in composition to MVs except for the 
absence of processed core proteins and that they remained associated with the D13 scaffold [95,96]. 
An inducible mutant of the A19 minor core component has shown that plaques and MVs do not  
form in the absence of inducer although the absence of A19 did not appear to affect the removal of  
D13 [97]. These cells contained only crescents, IVs and aberrant dense spherical particles that had 
little associated D13 scaffolding although they appeared to occasionally progress to being wrapped and 
exocytosed. Together, these examples serve to show that while removal the D13 scaffold is necessary, 
this alone is not sufficient for IVNs to progress to MVs. 
6.2. Membrane Restructuring to Form MVs Remains Controversial 
The MV membrane is distinguished from IVs by the presence of additional surface proteins.  
These proteins tend to have roles in cell attachment and mediating infection rather than morphogenesis 
but their presence can be considered important to the production of infectious MV and EV. Of recent 
note, while earlier roles of A17 have been discussed, its presence in the MV envelope later functions to 
anchor other viral proteins, such as A27 and A26, to the particle surface through direct or indirect 
interactions, respectively that is important for further development of MVs [98]. Membrane proteins 
A17 and A14 have been shown to associate with membranes in vitro in a co-translational manner  
only [59]. Their presence on both IV and MV membranes has suggested that the IV membrane remains 
at least part of the MV membrane. It is generally agreed that the intermediates between IVNs and MVs 
are short-lived as they are rarely observed and a number of models have been proposed to describe the 
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processing of the IVN membrane to form MVs (reviewed in [5,6]). One debated feature of the models 
includes whether the core is surrounded by a second lipid layer and recent studies have furthered the 
argument for an inner membrane. Using electron tomography, distortions in the mostly continuous IV 
membrane have been observed [99]. At these points, the membrane fragments overlapped and were 
considered potential sites where crescents came together. Some IVNs showed areas of disordered D13 
scaffold and in these regions, the membrane was described as having a waved aspect. A transient  
IVN-associated complex, speculated to have a role in maturation was also identified. The complex was 
usually located opposite the nucleoid attached to the inner side of the membrane with an extension that 
protruded outside of the virus particle. This study also identified putative intermediates that had a large 
number of discontinuities in the membrane and regions of overlapping membranes. Pieces of 
membranes also appeared to be forming core-like structures inside particles and areas of continuation 
between outer membrane pieces and internal membranes were observed. The absence of any evidence 
of continuity between the outer membrane and a lipid core wall had previously been used to favor the 
protein core wall model and the increased surface area of MVs compared to IVs was speculated to be 
accounted for by the insertion of membrane proteins or the presence of overlapping membranes that 
construct IVs. A recent study has imaged sub-strains of Western Reserve vaccinia with a number of 
accumulated mutations in the hope that there would be an increased amount of intermediate particles 
due to mutations blocking or decreasing the efficiency of virion morphogenesis. Similar fragmented IV 
membranes were detected and external pieces were seen connecting with internal structures that 
appeared to be developing a core shaped structure [32]. In summary, these studies propose that MVs 
contain external and internal membranes and that the inner membrane that surrounds the DNA core is 
the result of reorganization of the original IV membrane. It will be of interest to see these studies 
progress towards a working model explaining the signaling and protein interaction events that give rise 
to the intermediates described. 
6.3. Transcriptional Activity May Be Linked to a Stable Core Structure 
A protein shell surrounding the DNA has been evidenced by biochemical and imaging techniques 
but there is little understanding of the structure and organization within the core. Treatment with  
non-ionic detergents and reducing agents removes the outer membrane of virus particles to leave the 
cores intact. Prolonged protease treatment of these cores has produced AFM images of DNA spilling 
out of perforated or protease-damaged cores [100]. Inside of the proteinaceous shell, the genome is 
associated with DNA binding proteins along with the complete transcription machinery required for 
expression of early viral genes. If the transcription machinery is not packaged correctly and transcription 
is defective, the resulting MV may appear almost morphologically-normal but nevertheless are not 
infectious. Inducible mutant viruses deficient in core proteins L4/VP8 (DNA/RNA binding protein), 
L3 or H1 (protein phosphatase) have demonstrated this (reviewed in [5]) and likewise, temperature 
sensitive E8 mutants produced typical IV, IVN, and MV structures [101]. However, these virions were 
transcriptionally-defective so it is speculated that E8 may have a structural role that is directly or 
indirectly important for transcriptional activity. An essential subunit of the DNA-dependent VACV 
RNA polymerase is H4/rap94 and temperature sensitive or inducible H4 mutants failed to form 
plaques under non permissive conditions [102,103]. However, when infected cells were viewed by 
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EM, what were thought to be morphologically-normal MVs were present, demonstrating that the core 
and lateral bodies can form independently of transcription machinery assembly. More recently, cells 
infected with inducible H4 mutant viruses were prepared using high pressure freezing, freeze 
substitution treatment and ultramicrotomy to produce TEM images that would allow a detailed 
visualization of the internal structure of virions [104]. Compared to wild-type infections, the absence 
of H4 produced virions that had an empty or collapsed core from which it was inferred that the 
transcription machinery is involved with forming a stable core structure. 
6.4. Morphogenic Proteolysis Generates an Active Core 
Similarly to other viral systems, proteolytic processing is essential in regulating morphogenesis,  
by providing a means of activating proteins at the appropriate time. This has been evidenced by  
the inhibition of proteolysis preventing infectious MV generation in the absence of changes to protein 
synthesis (reviewed in [105]). Sequence comparison and experimental data of precursor and processed 
core proteins A10, A3, and L4 identified a common AG↓X motif (where X can be A, S, or T, but not 
N) as the cleavage site and I7 was later identified as the core protease [106]. Although I7 is expressed 
late in infection, it has been identified in viral factories, IVs and MVs where it is confined to the core 
[107]. Proteolytic processing of major core proteins occurs only during the IV to MV transition but 
how I7 activity is regulated to achieve this is currently unknown. However, I7 alone is not responsible 
for core maturation. G1 is currently the only other VACV protein with similarity to other known 
proteases. It contains an HXXEH zinc-binding motif, which is an inversion of the motif characteristic 
of matrix metalloproteinases. The absence of G1 results in the arrested development of virus particles 
after core protein cleavage but before core condensation has been completed, resulting in a lack of MVs 
[108,109]. G1 itself is cleaved by a currently unidentified protease and the significance of this is also 
currently unclear [110]. Together the evidence from I7 and G1 mutants suggest that the proteases 
function sequentially since I7 mutants show arrest morphogenesis prior to core condensation, while the 
absence of G1 activity arrests morphogenesis after core condensation has commenced but prior to its 
completion. 
6.5. Cellular Host Proteins Can Have Roles in Morphogenesis 
Viruses are notorious for exploiting pre-existing host pathways for their own needs. Host protein, 
Golgin-97 is a component of MVs and has been shown to co-locate with insoluble core proteins while 
the N-terminus extends outside of the virus [111,112]. Using RNAi to suppress golgin-97 expression 
resulted in significantly decreased virus titers and inspection by EM showed the absence of MVs and 
the accumulation of IVs but further study is required to determine the how golgin-97 is involved in the 
transition of IVs to MVs [111]. 
Host cell phosphatidylinositol 3-kinases (PI3Ks) have also been shown to regulate the transition of 
IVs to MVs and also envelopment of extracellular MVs (discussed later). Two compounds; AS1 and 
AS2 from a kinase inhibitor library were found to significantly reduce plaque size [113]. The role of a 
host PI3K was then confirmed by infection studies using cell lines deficient in PI3K activity which 
reduced plaque number. The presence of AS1 reduced late protein production and trafficking of F13 
Viruses 2014, 6 3799 
 
which may contribute to the decreased number of MV identified by EM compared to in the absence  
of AS1. 
Golgin-97 and PI3K are the most recent examples of the roles cellular proteins can have in  
virion morphogenesis. It will be of interest to observe what other host proteins will be found to be 
involved VACV morphogenesis in the future and how poxviruses exploit these host proteins to their  
own advantage.  
6.6. The VACV Redox System is Important for Functional Membrane Proteins Displayed on  
the MV Surface 
Repression of viral redox system proteins E10, A2.5 or G4 interrupts IVN transition to MV [114–
116]. These proteins control disulphide bond formation in the typically reducing cytoplasmic 
environment and regulate the functions of a number of proteins including L1, A28, A21, L5 and H2. 
Common to these proteins is a transmembrane domain and localization to the MV membrane 
(reviewed in [117]).  
6.7. Lateral Bodies Package Viral Proteins in Preparation for Delivery to the Cytosol of Host Cells  
Complementing EM images, atomic force microscopy has also provided evidence for the presence 
of two lateral bodies (LBs) attached to opposing side of the MV core that were susceptible to protease 
treatment and may give the core its characteristic biconcave morphology [100]. There is little 
speculation on when and how these lateral bodies form and attach to the core. It has recently been 
proposed that lateral bodies facilitate the delivery of viral enzymes to the host cell cytosol [118].  
This study used immunogold staining to identify F17 (also known as F18, p11, or VP11) as the main 
component of LBs although VH1 and G4 were also identified as being delivered into cells by LBs 
where proteasomes may contribute to LB disassembly upon which, F17 is rapidly degraded leading to 
speculation that F17 is a LB scaffold protein. These components are thought to account for only a 
fraction of the LB mass so other proteins that may modulate host cell processes or prevent virus 
recognition may become apparent in future studies. Curiously, repression of F17 from an inducible 
mutant has also been shown to generate only crescents and aberrant IVs with unusual internal 
membranes and nucleoids, morphologically-sound, infectious MVs were absent [119,120].  
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Figure 2. A summary of the transition of immature virion (IV) to mature virion (MV). I7 
proteolysis has a role in removing the D13 scaffold by proteolytic processing of the 
membrane protein A17 (1). Core proteins are also cleaved by I7 into their mature forms 
(2). In the absence of the D13 scaffold the IV transitions towards becoming a MV and 
possibly involves rearrangement of the IV membrane into an inner and outer membrane 
(3). G1 activity is required to complete core condensation (4). The resulting MV contains a 
biconcave core that contains the viral genome and core proteins including the transcription 
apparatus required for early gene transcription. Lateral bodies are located outside of the 
core and enclosed by the MV membrane. The MV membrane contains additional proteins 
which can have functions that facilitate progression to enveloped MV (EV).  
7. A Subset of MVs Go on to Form Enveloped Virions 
Mature virions are transported out of viral factories and subsets of MVs are processed further to 
become enveloped virions (EVs) which support dissemination of the virus from cell to cell within an 
infected host. Microtubules traffic these MVs, which become wrapped in a double membrane derived 
from the trans-Golgi network or endosomes that incorporate viral proteins A33, A34, A36, A56, B5, 
E2, F12, F13, and K2. Wrapping and subsequent generation of EVs is known to require A27, B5 and 
F13 (also known as p37) (see [6] for review). A few studies have since expanded on the role of these 
proteins. F13 was recently shown to associate with late endosome host proteins and this interaction 
was required for plaque formation and wrapped virions [121]. A recombinant virus with B5 and A33 
deleted, inhibited plaque formation almost completely whereas deletion of either B5 or A33 only 
reduced plaque size compared to the parent VACV [122]. The intracellular enveloped virus or wrapped 
virion can then fuse with the plasma membrane where it either remains associated with the cell or the 
formation of actin tails beneath the cell-associated EV promotes extracellular release of the virus or 
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transmission to neighbor cells. Envelope proteins are thought to maintain the association of EVs with 
the cell and A36 was shown to promote release of EVs since certain amino acid substitutions abolished 
the commencement of actin tail formation and reduced EV release [123]. Cellular proteins FHOD1 and 
Rac1 have also recently implicated in actin tail formation and growth [124]. 
8. Conclusions and Open Questions 
Clearly, the morphogenesis of VACV is a complex process. Different stages of morphogenesis can 
proceed concurrently and host proteins also have important roles in the process of forming crescents 
which assemble into IVNs and then progress to the infectious forms of VACV. Future advances in 
imaging techniques will likely resolve the sub-viral structure and further genetic and biochemical 
studies will increase our understanding of the protein interactions that progress and regulate 
morphogenesis. This intimate understanding of the morphogenesis of VACV will facilitate the future 
rational design of safe, immunogenic vaccine candidates or effective antivirals. 
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